You are here

  • Home
  • Archive
  • Volume 18, Issue 3
  • Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

Article metrics

Article menu
Download PDFPDF
ORIGINAL ARTICLE
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

 

Online download statistics by month:

Online download statistics by month: March 2019 to April 2024

AbstractFullPdf
Mar 20191400
Apr 20191200
May 20192303
Jun 2019700
Jul 2019600
Aug 2019600
Sep 2019200
Oct 2019600
Nov 2019200
Dec 2019600
Jan 2020900
Feb 2020800
Mar 2020200
Apr 2020400
May 20201000
Jun 2020600
Jul 20201000
Aug 2020400
Sep 2020800
Oct 20204000
Nov 20201801
Dec 2020600
Jan 20212900
Apr 2021800
May 2021600
Jun 2021002
Aug 2021100
Oct 2021800
Nov 2021400
Dec 20211100
Jan 2022900
Feb 20221300
Mar 20222000
Apr 20221402
May 20223600
Jun 20223400
Jul 20221400
Aug 20223000
Sep 20223000
Oct 20223800
Nov 20221200
Dec 20221801
Jan 2023200
Feb 20236600
Mar 2023400
May 2023800
Jun 2023700
Jul 2023400
Aug 2023401
Sep 2023800
Oct 2023600
Nov 2023400
Dec 20231600
Jan 2024800
Feb 2024400
Mar 20241200
Apr 20241600
Total713010